This Plain Language Summary of Publication from Future Oncology describes the results of a 5-year study comparing combinations of drugs for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cell cancer.
Read the full article here
The original article on which this Plain Language Summary of Publication is based is titled ‘Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study’ and was published in the Journal of Clinical Oncology. Read the original article here.